Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.

Also called NCT03183245

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 242 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03183245
Other papers using this trial's data
  • Bioengineered acellular tissue engineered vessels versus autogenous fistulae for haemodialysis access: a multicentre, randomised, controlled, phase 3 trial The Lancet. Digital health, 2026-08 DOI, PubMed 42613284

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03183245. Randomized; no masking; primary purpose treatment. Start 2017-09-29 (actual); primary completion 2024-04-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
Condition
Renal Failure
Condition
End Stage Renal Disease
Condition
Hemodialysis
Condition
Vascular Access
Intervention (Biological)
Human Acellular Vessel (HAV)
Intervention (Procedure)
Arteriovenous fistula (AVF)
Intervention (Other)
Hemodialysis
Lead sponsor
Humacyte, Inc. (class: industry)
Collaborator
CTI Clinical Trial and Consulting Services (class: other)
Collaborator
California Institute for Regenerative Medicine (CIRM) (class: other)

Record details

Record id
cardio:ct-nct03183245
Content hash
a87ddf0589faf476c792f0bfce8b1ed7fd50c230bebe5120c90c6f79b06744b0